enGenes Biotech has developed Intellectual Property (IP) and has patents pending on its enGenes-eXpress™ technology which forms a growth-decoupled microbial protein production system for optimized protein expression in Escherichia coli (E. coli).
This prokaryotic protein expression system allows enGenes Biotech to offer a range of highly relevant products and services to companies seeking develop cost-effective manufacturing processes for recombinant proteins. Overall, the technology is able to speed-up upstream process development timelines, reduces manufacturing costs through increasing product titers and enables more effective downstream processing due to high specific product yields (“more product with less biomass” due to the growth decoupled technology feature).
For more information follow https://www.pharmaceutical-networking.com/optimized-protein-expression-in-escherichia-coli-e-coli/
Comments